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ABSTRACT 
 
MET oncogene amplification is emerging as a major mechanism of acquired 
resistance to EGFR-directed therapy in lung and colorectal cancers. Further, MET 
amplification predicts responsiveness to MET inhibitors currently in clinical trials. 
Among the anti-MET drugs available, ATP-competitive small molecule kinase 
inhibitors abrogate receptor autophosphorylation and downstream activation of 
ERK1/2 and AKT, resulting in cell cycle arrest. However, this anti-proliferative effect 
allows persistence of a pool of cancer cells that are quiescent but alive. Once the 
inhibition is removed, rebound activation of MET-driven cell proliferative pathways 
and tumor growth may occur, an adverse event observed frequently in clinical settings 
after drug discontinuation. Here we show that inhibitor withdrawal prompts receptor 
phosphorylation to levels higher than those displayed at steady-state and generates a 
rebound effect pushing quiescent cancer cells back into the cell cycle, both in vitro 
and in experimental tumor models in vivo. Mechanistically, we found that inhibitor 
treatment blocks MET endocytosis, causing a local increase in the number of 
receptors at the plasma membrane. Upon inhibitor washout, the receptor is readily re-
phosphorylated. The initial phosphorylation is not only increased but also prolonged 
in duration due to downmodulation of a phosphatase-mediated MET negative 
feedback loop which accompanies receptor internalization. Notably, treatment with a 
MET therapeutic antibody that induces proteolytic cleavage of the receptor at the cell 
surface substantially prevents this rebound effect, providing a rationale to combine or 
alternate these mechanistically different types of MET-targeted therapy. 
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INTRODUCTION 
 
Receptor tyrosine kinases (RTKs) are major targets for pharmaceutical inhibition due to their 
crucial role in oncogenesis and progression of many solid tumors. Several small molecular 
weight inhibitors have been developed that, by inhibiting tyrosine kinase activity of 
oncogenic RTKs, abrogate their downstream signaling cascade and impair cancer cell 
proliferation (1).  
The rationale of targeting the MET kinase stems from the observation that this receptor is 
aberrantly activated in tumors. Upregulation is achieved by gene amplification, enhanced 
transcription or ligand-dependent autocrine loops (2,3). Moreover, activating somatic 
mutations have also been reported (2,4). Tumors carrying MET amplification are dependent 
on MET signaling for growth and survival, as inhibition of MET in MET-amplified cancer 
cells severely impairs cell proliferation, a phenomenon termed ‘oncogene addiction’ (5). In 
‘addicted cells’, MET kinase inhibition abrogates downstream ERK1/2 and AKT 
phosphorylation, resulting in cell cycle arrest. However, even under conditions of prolonged 
pharmacological MET inhibition, a pool of cells remains quiescent without being irreversibly 
committed to apoptosis and resume growth after release of MET blockade (6). Although the 
molecular mechanisms of tyrosine kinase inhibitors have been extensively studied, the effects 
of drug withdrawal on cancer cells are still largely unexplored.  
Here we investigated the effects of removal of a MET kinase inhibitor both in vitro and in 
experimental tumor models in vivo.  
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MATERIALS AND METHODS 
 
Cell culture 
A549, H1993 and EBC-1 cells were grown in RPMI, Hs746T in Iscove’s Dulbecco modified 
medium (Sigma) supplemented with 10% FBS (Euroclone) and 1% glutamine. A549, H1993 
and Hs746T cells were obtained from the European Collection of Cell Cultures, EBC-1 cells 
were from the Japanese Collection of Research Bioresources.  
The genetic identity of the cell lines was confirmed by short tandem repeat profiling (Cell ID, 
Promega), which was last repeated in November 2015. Cells were periodically tested and 
resulted negative for mycoplasma contamination with Venor GM kit (Minerva biolabs). 
 
Immunofluorescence and quantifications 
In the endocytosis assays, cells were plated on 24 well plates (50.000 cells/well for A549 and 
H1993, 70.000 cells/well for Hs746T). The day after, cells were starved in serum free 
medium supplemented with 0.2% BSA for 4 hours at 37°C then incubated for 1 hour at 4°C 
in presence of HGF [50 ng/ml] or of purified anti-MET (DO24) or control unrelated 
antibodies [85.7 μg/ml]. JNJ-605 300nM was added or not during this incubation step and 
left throughout the following internalization step. Cells were then shifted at 37°C for 15 min 
to allow MET endocytosis. Immunofluorescence was as in (7) staining cells with anti-MET 
(DO24) and anti-EEA1 antibodies. Primary antibodies were revealed by Alexa Fluor 555-, 
488- (Molecular Probes, USA) conjugated secondary antibodies. Confocal analysis was 
performed on a Leica TCS SP5 AOBS microscope and processed in Adobe Photoshop. 
Immunofluorescence acquisition settings were kept constant within each cell line. 
Quantitative analyses of co-localization were carried out with ImageJ software 
(http://rsb.info.nih.gov/ij/) using the JacoP plugin (Manders coefficient). The phospho-MET 
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and total MET ratio was calculated with ImageJ measuring the mean pixel intensity in each 
channel, background subtracted.  
 
Endocytosis and Recycling biochemical assays 
Endocytosis and Recycling assays were performed following the protocol described in (8,9). 
Briefly, cells were labeled at 4°C with 0.5 mg/ml sulfo-NHS-SS-biotin (ThermoScientific) in 
PBS for 30 min in presence or absence of 500nM JNJ-605. After washing, cells were 
transferred to pre-warmed medium and incubated at 37 °C for 15 min to allow endocytosis of 
biotinylated receptors in presence or absence of 500nM JNJ-605. In A549 cells, MET 
endocytosis was stimulated by treatment with HGF (50 ng/ml). Biotinylated MET was 
captured by overnight incubation of 50 μl cell lysate at 4°C using 96 multi-well immuno-
plate (Sigma M5785-1Cs) coated with 5 μg/ml anti-MET DO24 antibody and revealed by 
ELISA with streptavidin-conjugated horseradish peroxidase (Amersham) followed by a 
chromogenic reaction with ortho-phenylenediamine (Sigma).  
 
Measurement of surface MET 
Cells were plated on 10 cm dishes (A549 and Hs746T 1.5 x 106 cells/well, EBC-1 2 x 106 
cells/well) and treated, the day after, with JNJ-605 500nM for 2, 10 or 24 hours.  
Cells were rinsed three times with cold PBS and surface receptors were biotinylated for 30 
min at 4°C using the ECL protein biotinylation kit (GE Healthcare) according to the 
manufacturer’s instructions. Cells were lysed in EB buffer: [20 mM Tris HCl pH 7.4, 2 mM 
EGTA, 5 mM EDTA, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 50 mM Hepes]. Total 
cellular lysates were cleared by centrifugation and MET was immunoprecipitated from 300 
μg of A549, 25 μg of EBC-1 and 50 μg of Hs746T of lysates with the anti-MET DQ13 
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antibody. Samples were run on SDS PAGE and blotted with HRP-conjugated streptavidin 
(GE Healthcare) and with anti-MET antibody DL21. 
 
Analysis of inhibitor withdrawal in immunofluorescence, western blot, Multiplex 
phosphoproteomic and Cytofluorimetric experiments  
In the immunofluorescence experiments H1993 cells were plated on 24 well plates (50.000 
cells/well). The day after, cells were treated or not with 500nM JNJ-605 for 17 hours and 
then released by washing three times with 1 ml of medium. Next cells were incubated at 37°C 
with fresh medium for 15 min, then the entire procedure was repeated. Cells were fixed at 
various time points and stained.  
For western blotting, MesoScale and cytofluorimetric experiments H1993 and EBC-1 cells 
were plated (400.000 cells in 19.5 cm2 plate), treated or not with JNJ-605 500nM for 17 
hours. Cells were released by washing them 3 times with 4 ml of medium and re-incubated at 
37°C with fresh medium. After 15 min the release procedure was repeated. Samples were 
processed after the release at different time points as indicated. When indicated, MvDN30 
and control Fab unrelated antibodies (50 μg/ml) were added after the second washout and 
cells were harvested 24 hours later. Western blot samples were lysed in EB buffer.  
For the multiplex phosphoproteomic analyses we used commercially available plates from 
MesoScale Discovery of phospho-ERK/total ERK and phospho-AKT/total AKT. After 
incubation with protein extracts, detection was performed by quantitative 
electrochemiluminescence with reported antibodies coupled with SULFO-TAG as described 
in (6). The percentage of phosphorylated protein was calculated with the following formula: 
% phosphoprotein = [(2xphospho-signal)/(phospho-signal + total-signal)] x100. The 
percentage obtained was control subtracted, converted in logarithmic form and represented 
with the heat maps generated by the freeware Gedas program (10). 
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Cytofluorimetric analysis was performed using the Click-iT® EdU Alexa Fluor® 647 Flow 
Cytometry Assay Kit (Life Technologies). Cells were incubated for 2 hours with 10nM EdU, 
a thymidine analogue that is incorporated into DNA during DNA synthesis. Next cells were 
washed once with PBS and once with PBS 1% BSA, fixed, permeabilized and stained 
following the manufacturer’s protocol. Samples were acquired using the CyAn ADP 
(Beckman Coulter). For statistical analyses the non-parametric Mann-Whitney test was used.  
 
In vivo experiments 
All animal procedures were performed according to protocols approved by Ethical 
Committee for animal experimentation of the Fondazione Piemontese per la Ricerca sul 
Cancro and by Italian Ministry of Health. Mice (female non-obese diabetic/severe combined 
immunodeficient -NOD/SCID- mice) were purchased from Charles River Laboratories. EBC-
1 cells, 1.8 x106 cells/mouse were injected subcutaneously into the right posterior flank of 6-
week-old NOD-SCID mice. Tumor growth was evaluated periodically with a caliper and 
tumor volume was calculated as described (11). After 19 days, when masses reached on 
average tumor volumes of 118.5 ± 56 mm3 mice were randomized and divided in 4 groups: 
one group was untreated (CTR, n=5), while the other 2 groups were treated with JNJ-605 (50 
mg/kg) by gavage every 24 hours for 5 days. Of these, one did not receive any further 
administration (w/o JNJ-605, n=6) while the other (w/o JNJ-605 w MvDN30PEG, n=5) was 
treated with MvDN30-PEG (12) (15 mg/kg) every three days (day 23, 26, 29). At day 29, 
mice were injected intra-peritoneally with 75 μg/mouse of EdU in 200 μl of PBS. Twenty-
four hours later mice were sacrificed and tumor were extracted, formalin-fixed, embedded in 
paraffin and sectioned. Tumor slices (3 μm thickness) were processed to highlight cells 
having incorporated EdU. Briefly, paraffin removal was performed with two 10 minutes steps 
in Xylene, slices were then washed twice with BSA 3% in PBS for 5 minutes, permeabilized 
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in PBS, 0.1% TritonX-100 (20 minutes at RT) and stained using the Click-iT® EdU 
AlexaFluor® 555 Imaging Kit (Life Technologies), following the manufacturer’s 
instructions and with DAPI.  
Statistical analysis was performed with Graphpad software using the non-parametric Mann-
Whitney test. 
The sources and applications of antibodies, growth factors and chemicals are detailed in the 
Supplementary Materials and Methods along with methods for the endocytosis assays shown 
in Supplementary Fig. S1, the HGF labeling and the in vivo experiment of Supplementary 
Fig. S6.  
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RESULTS 
 
Kinase inhibition blocks MET endocytosis, but not recycling from endosomal 
compartments 
 We initially looked at the effects of MET kinase inhibition on the intracellular 
distribution of the receptor in MET-amplified H1993 (non-small cell lung cancer) and 
Hs746T (gastric cancer) cells (13). At steady state, MET localized mainly at the plasma 
membrane and in EEA1-positive early endosomes (Fig. 1A,D). Treatment with the MET-
specific ATP-competitor JNJ-605 for two hours at 37°C abruptly reduced the amount of MET 
in early endosomes (Fig. 1A-F), suggesting that kinase inhibition blocks MET internalization 
and/or its intracellular trafficking.  
First, we investigated whether the inhibition of MET kinase activity interferes with receptor 
endocytosis, either constitutive or induced by the ligand Hepatocyte Growth Factor (HGF), or 
by the agonistic anti-MET antibody, DO24 (14). The percentage of MET co-localizing with 
EEA1 in early endosomes was evaluated as a measure of receptor endocytosis. In the A549 
cell line, featuring a normal gene copy number and expressing physiological amounts of the 
receptor at the surface, stimulation with HGF or DO24 caused MET endocytosis in EEA1-
positive endosomes (Fig. 2A, top row, and C). In untreated H1993 and Hs746T cells, the 
amount of MET in endosomes was higher compared to A549 cells (Fig. 2A, middle and 
bottom rows, and C) indicative of constitutive endocytosis which likely results from basal 
phosphorylation of MET in these cell lines (13,15,16). Inhibition of MET kinase activity by 
JNJ-605 prevented MET endocytosis triggered by any treatment or resulting from receptor 
overexpression (Fig. 2B,C and Supplementary Fig. S1A-C).  
These findings were verified biochemically taking advantage of surface protein biotinylation. 
Receptors at the plasma membrane were labeled with a cleavable form of biotin (sulfo-NHS-
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SS-biotin) and subjected to endocytosis. After cleavage of biotin from receptors remaining at 
the cell surface, the amount of internalized biotinylated MET was measured. Results 
confirmed that JNJ-605 severely affects MET endocytosis (Fig. 2D). This was not due to a 
general impairment of endocytic pathways, as treatment with JNJ-605 did not prevent ligand-
induced EGFR endocytosis (Supplementary Fig. S2A,B).  
In MET-amplified cells, receptor constitutive activation is the consequence of spontaneous 
dimerization/trans phosphorylation due to increased local density of the kinase [(16) and 
reviewed in (2)]. We therefore tested whether MET dimerization could be a pre-requisite for 
receptor endocytosis. To this end, we took advantage of a decoy MET receptor that 
encompasses the MET extracellular domain and binds to the full-length receptor, thus 
preventing MET homo dimerization and activation (17,18). In agreement with the ability of 
the decoy to reduce MET trans phosphorylation (17,18), we found that it severely affected 
both ligand-induced and constitutive MET endocytosis (Supplementary Fig. S3A,B). 
We then assessed if MET kinase inhibition leads to receptor accumulation at the plasma 
membrane. A549 and the MET-amplified cell lines Hs746T and EBC-1 were treated with 
JNJ-605 for 2, 10 or 24 hours, and proteins exposed at the cell surface were labeled with non-
cleavable biotin. Total MET was immuno-precipitated from the various conditions and the 
amount of labeled surface receptor was revealed by streptavidin. In agreement with our initial 
observation (Fig. 1A-F) and with the endocytosis data (Fig. 2A-D), treatment with JNJ-605 
increased the amount of MET at the cell surface in all tested cell lines (Fig. 3A). This effect 
was not restricted to JNJ-605 but was exerted also by other MET kinase inhibitors such as 
PHA665752 and crizotinib (Fig. 3B).  
Finally, we evaluated whether inhibition of MET kinase activity might alter recycling from 
endosomal compartments using a pulse-chase approach with sulfo-NHS-SS-biotin. The 
amount of biotinylated MET remaining within endosomal compartments after chasing for 15 
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or 30 minutes, in the presence or absence of JNJ-605, was assayed by capture-ELISA. While 
JNJ-605 inhibited MET endocytosis (Fig. 2A-D), it had no effect on the amount of its 
intracellular pool in any cell line tested (Fig. 3C). Thus, our results show that 
pharmacological kinase inhibition blocks MET endocytosis, but not recycling, causing 
accumulation of the receptor at the plasma membrane. 
 
Removal of the MET inhibitor JNJ-605 causes rebound effects on kinase 
phosphorylation and cell proliferation 
We initially analyzed re-phosphorylation of MET following inhibitor withdrawal in time 
course immunofluorescence experiments on H1993 cells treated with JNJ-605 overnight and 
then released from inhibition through a rapid washout procedure. We observed that the 
amount of phospho-MET increased rapidly after inhibitor washout becoming markedly 
higher, compared to control, 2 hours after the release, with a peak around 8 hours (Fig. 
4A,B). This abrupt re-phosphorylation was transient as it went back to control levels between 
48 and 72 hours following release (Fig. 4A,B). Following drug withdrawal, we detected a 
small fraction of phospho-MET on early endosomes (Fig. 4C). The extent of internalization 
of the active receptor was modest immediately after treatment discontinuation, and reached 
control levels along time (Fig. 4C) indicating that endocytosis resumed with slow kinetics. 
MET re-phosphorylation was confirmed by immunoblotting of lysates from H1993 and EBC-
1 cells (Fig. 4D). 
To explore the mechanisms underlying this prolonged and increased MET activation after 
drug removal, we investigated whether negative regulators of MET phosphorylation could be 
affected by MET blockade and subsequent release. Among the phosphatases known to act on 
MET, PTP1B plays a major role being responsible for dephosphorylation of tyrosines 1234 
and 1235 within the MET catalytic domain (19). Autophosphorylation on these residues is 
 13
required for subsequent phosphorylation on other tyrosines in the MET docking site and for 
full MET activation (20,21). Importantly, loss of PTP1B is known to cause MET hyper-
phosphorylation (19).  
We found that PTP1B protein expression was reproducibly reduced, both in the EBC-1 and 
H1993 cell lines, upon JNJ-605 treatment; this down-modulation was maintained after 
inhibitor washout, inversely correlating with the increased MET phosphorylation (Fig. 4D). 
Although the molecular underpinnings of PTP1B modulation remain to be determined, these 
findings point to down-regulation of PTP1B as a potential mechanism to promote rebound 
MET hyper-phosphorylation after drug removal.  
To investigate the effects of increased receptor activity we looked at ERK1/2 and AKT as 
these are the two major MET-dependent pathways that sustain growing and survival in the 
MET-amplified cells (6). Multiplex quantitative assessment confirmed that release from JNJ-
605 increased ERK1/2 re-phosphorylation of about 2-fold both in EBC-1 and H1993 cells 
(Fig. 5A). The increase measured on AKT was of about 1.5-fold in both cell lines (Fig. 5A).  
Finally, we investigated whether the observed rebound phosphorylation and activation of 
MET signaling pathways was accompanied by re-entering of cells into the cycle. We found 
that, in H1993 and EBC-1 cell lines, the number of cells in S phase 24 hours after inhibitor 
washout was nearly doubled compared to controls (Fig. 5B).  
Based on the extensive crosstalk between MET and other RTKs, we investigated whether 
rebound activation would also involve other receptors. Stimulation with EGF, NRG1-β1 or 
PDGF did not increase the S-phase entry of cells following inhibitor withdrawal 
(Supplementary Figure S4A). Moreover, phosphorylation of EGFR and HER3 was not 
significantly enhanced by JNJ-605 washout (Supplementary Figure S4 B,C). Thus, massive 
entry of cells into S-phase following inhibitor withdrawal appears to depend primarily on 
MET activation.  
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In conclusion, removal of an ATP-competitive, reversible, MET inhibitor restores MET 
phosphorylation and signaling, re-programming cells for proliferation.  
 
Treatment with a MET therapeutic antibody abrogates rebound MET activation in 
vitro 
We tested whether the rebound effect, generated by kinase inhibition removal, could be 
prevented by a complementary pharmacological treatment, such as the therapeutic 
monovalent DN30 (MvDN30). This antibody down regulates the receptor by stimulating the 
activity of proteases at the cell surface (22). MvDN30 has no agonistic effect on MET (11), 
including the ability to trigger endocytosis (shown in Supplementary Fig. S1, shedding 
activity is shown in Supplementary Fig. S5).  
We found that, when MvDN30 was added to EBC-1 cells immediately after inhibitor 
washout and kept for 24 hours, it led to almost complete abrogation of ERK1/2 and AKT 
phosphorylation, consistent with the down-regulation of the MET protein (Fig. 6A). In 
agreement, addition of MvDN30 after JNJ-605 removal severely dampened re-entry of cancer 
cells into the cycle (Fig. 6B) preventing the rebound effects caused by kinase inhibitor 
washout.  
In a complementary approach, we tested whether removal of MvDN30 from cells that were 
pre-treated exclusively with the antibody could result in rebound effects. Differently from 
JNJ-605, removal of MvDN30 did not promote MET/ERK/AKT re-phosphorylation and, 
consistently, it did not enhance cell entry into S-phase (Fig. 6C, D).  
 
Discontinuation of the MET kinase inhibitor restores tumor cell proliferation and is 
counteracted by MvDN30 treatment in vivo  
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Based on the results obtained in vitro, we investigated whether JNJ-605 withdrawal might 
cause rebound MET activation and cancer cell growth in vivo. We initially evaluated the 
occurrence of rebound S-phase entry in experimental tumors established by injecting EBC-1 
cells subcutaneously into NOD-SCID mice. When tumor size reached approximately 90 
mm3, mice were randomized and subjected to oral administration of JNJ-605 for five days. A 
control group of animals (CTR) did not receive the drug (Supplementary Fig. S6A). We 
measured the percentage of cells that entered the S phase of the cycle by injecting EdU, a 
thymidine analogue that is incorporated in the DNA of duplicating cells, 24 hours before 
harvesting the tumors. In the tumors in which treatment with JNJ-605 was interrupted for 3 
and 5 days the number of proliferating cells was markedly higher compared to untreated 
tumors and it was accompanied by increased MET phosphorylation and ERK activation 
(Supplementary Fig. S6B,C). These findings show that discontinuation of the anti-MET 
kinase inhibitor favors marked and rapid resumption of tumor proliferative activity by 
rebound reactivation of the MET receptor and its downstream signaling cascade. 
Next we investigated the ability of MvDN30 to counteract the rebound effect. To this end, we 
repeated the experiment. Two groups of animals were treated with JNJ-605 for five days; 
then, treatment was discontinued. One group was left untreated, while the other was 
intraperitoneally administered with MvDN30-PEG, the chemically stabilized form of 
MvDN30, suitable for in vivo application (12). After 7 days all animals, including the 
controls, were sacrificed (Fig. 7A). The burst of S-phase cells and the increase of MET/ERK 
activation induced upon JNJ-605 withdrawal were abrogated in the tumors that received 
MvDN30-PEG (Fig. 7B-D). Analysis of tumor volumes revealed that, after a short period of 
latency (three days), therapy dismissal resulted in tumor regrowth (Fig. 7E). Treatment with 
MvDN30-PEG, after JNJ-605 withdrawal, partly impaired this tendency (Fig. 7E). These 
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findings show that the resumption of tumor proliferative activity occurring upon 
discontinuation of the anti-MET kinase inhibitor is dampened by MvDN30-PEG treatment. 
  
 17
DISCUSSION  
In clinical settings, discontinuation of tyrosine kinase inhibitors such as erlotinib and 
crizotinib has been found associated with a significant risk of rebound cancer growth or 
accelerated disease progression (“disease-flare”) (23,24). Targeted therapy is usually 
discontinued when, after initial response, patients demonstrate disease progression, indicative 
that they have acquired resistance to the drug. However, because of the reported “flare”, it 
has been recently recommended to minimize the washout period in this patient population 
before starting with a second line therapy or to continue it concurrently with the new 
treatment (25). Here, we provide evidence that release of MET blockade after treatment with 
a MET small-molecule inhibitor leads to rebound MET activation and cell proliferation both 
in vitro and in experimental tumors in vivo.  
Treatment with MET inhibitors blocks MET endocytosis, increasing the number of receptors 
at the plasma membrane. Rise in receptor concentration at the cell surface has been shown to 
promote trans phosphorylation, likely by favoring receptor dimerization (2,16). Accordingly, 
interfering with receptor dimerization through a decoy receptor inhibits MET trans 
phosphorylation and endocytosis [(17,18) and this study], supporting the role of increased 
receptor clustering in the rapid re-phosphorylation of MET after inhibitor washout. This 
initial re-phosphorylation is then enhanced and prolonged likely by the reduced expression of 
a critical MET-negative regulator, the phosphatase PTP1B (19). Loss of PTP1B not only 
increases MET phosphorylation and signaling, but it also dampens receptor trafficking to the 
early endosomal compartment (19,26), thus, the observed reduction in PTP1B levels could 
also account for the delayed kinetics of receptor endocytosis following inhibitor withdrawal. 
Even if the active receptor is primarily present at the cell surface during drug washout, a 
small fraction of phospho-MET can be detected on early endosomes. As early endosomes 
represent a relevant platform for activation of MET downstream pathways [(27-29) and 
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reviewed in (30)], endosomal MET signaling likely participates to the rebound effect.  
 The increased MET activation and cell entry into the S phase that we observed in vitro 
are reproduced also in vivo after treatment discontinuation. Even if the rebound effect is 
transient, it appears to be sufficient to resume tumor growth, with potential implications in 
the emergence of genetically fitter subclones or in the expansion of cancer stem cell 
subpopulations.  
 Among the strategies to target MET in cancer, antibodies have been generated 
including the monovalent MvDN30 (5) whose therapeutic efficacy has been shown so far 
only on experimental tumor models (11,12). Of note, treatment of cancer cells resistant to 
MET kinase inhibitors with the MvDN30 antibody severely reduces their viability (31). This 
re-sensitization of resistant cells to MET inhibition relies on the ability of MvDN30 to 
function synergistically with MET kinase inhibitors (31), as it exploits a different mechanism 
of action whereby the antibody induces protease-mediated receptor shedding from the cell 
surface. Based on this evidence, it has been proposed that discontinuous, combined treatment 
by MvDN30 and chemical inhibitors may increase the clinical response bypassing resistance 
to anti-MET target therapies (31). The evidence that MET blockade by kinase inhibition led 
to MET accumulation at the cell membrane as well as rebound phosphorylation and cell-
cycle entry after inhibitor washout, with delayed endocytosis, provide the rational to test 
MvDN30 as a means to curb the rebound effect by removing MET from the cell surface. Our 
findings that, indeed, treatment with MvDN30 abolished the rebound effect further support 
the rationale of combined or alternate anti-MET therapies.  
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FIGURE LEGENDS 
 
Figure 1. Effects of kinase inhibition on MET localization.  
Confocal images of H1993 (A) and Hs746T cells (D) mock treated or treated with 300nM 
JNJ-605 (indicated on top) for 2 hours at 37°C. Merged images show MET (green), EEA1 
(red) and DAPI (blue). Portions of the endosomal compartment are boxed in the images and 
magnified in the insets below. Arrows point to the plasma membrane. Bar, otherwise 
specified, is 10 μm. B) and E) Bar graphs showing the percentage of MET that co-localizes 
with EEA1 in H1993 (B) and Hs746T (E) cells  (means ± s.e.m; n=8). C) and F) 
Immunoblotting of total cellular lysates from H1993 (C) and Hs746T (F) cells. 
 
Figure 2. Kinase inhibition blocks MET endocytosis.  
A) MET endocytosis was assayed in A549, H1993 and Hs746T cell lines untreated (CTR) or 
treated for 15 min with HGF, or anti-MET antibody DO24, or control antibody (Ab unr.) in 
absence (mock) or presence of 300nM JNJ-605 (JNJ-605). Merged images show MET 
(green), EEA1 (red) and DAPI (blue). Magnifications show part of the endosomal 
compartment. B) MET endocytosis assays in presence of JNJ-605. C) Quantification of the 
percentage of MET that co-localizes with EEA1. Black bars, untreated cells, red bars cells 
treated with JNJ-605. Means ± s.e.m, n=8. CTR vs HGF- or DO24-treated cells #p < 0.0001. 
Untreated vs JNJ-605-treated cells **p < 0.005. D) Biochemical endocytosis assays. Bar 
graphs represent the amount of internalized biotinylated MET in the cell lines indicated on 
top in untreated cells (black bars) or in cells subjected to JNJ-605 inhibition (red bars). Data 
are expressed as the percentage of internalised receptor, relative to the total amount of cell 
surface–labeled receptor. Values are the mean of three independent experiments ± SD 
performed in triplicate. *** p < 0.0005.  
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Figure 3. Inhibition of MET kinase causes receptor accumulation at the plasma 
membrane. 
A) A549, Hs746T and EBC-1 cells were treated with JNJ-605 500nM for 2, 10 or 24 hours at 
37°C, surface receptors were biotinylated and MET was immunoprecipitated (IP). Total 
lysates were run in input lanes (20 μg A549, 3 μg Hs746T and EBC-1). Streptavidin (strept.) 
reveals the amount of MET that accumulates at the plasma membrane. Immunoblotting was 
as indicated on the left. B) Hs746T cells were treated with different MET inhibitors (500nM) 
JNJ-605, PHA and crizotinib (CRIZ.) for 2 hours or over night and processed as in A). 
Immunoblotting was as indicated on the left.  Total lysates were run in input lanes. C) MET 
recycling in the A549, Hs746T and EBC-1 cell lines. The amount of biotinylated MET 
remaining after chasing cells for 15 or 30 min in presence or absence of JNJ-605 was 
determined by capture-ELISA. The percentage of MET recycled to the plasma membrane is 
expressed as the difference between the amount of MET initially labeled at the cell surface 
and the intracellular biotinylated pool remaining after chasing [as in (8)]. Values are the mean 
of two independent experiments ± SD, each point done in triplicate. P values not 
significative. 
 
Figure 4. Inhibitor washout promotes rebound MET activation. 
A) H1993 cells were treated overnight with 500nM JNJ-605 and fixed (JNJ-605), or released 
from the inhibition and fixed at the time points indicated on top. Controls (CTR) are 
untreated cells. Confocal merged images show total MET (green), phospho-MET (red), 
EEA1 (magenta) and DAPI (blue). B) Bar graph reporting the ratio of pixel intensity between 
phospho- and total MET (means ± s.e.m, n=8). C) Bar graph showing the percentage of 
phospho-MET that colocalizes with EEA1 (means ± s.e.m, n=8). D) Total cellular lysates 
from H1993 and EBC-1 cells treated as in A) were run on two different gels. We 
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immunoblotted one gel (run with 40 μg of lysates) with anti-phospho-MET and anti-MET 
(total) antibodies, the second gel (run with 10 μg of lysates) with anti-PTP1B and anti-β-
tubulin. Heat maps below the western blots represent the amount of PTP1B levels normalized 
on β-tubulin measured by densitometry. Mean values from two independent experiments. 
 
Figure 5. Inhibitor washout promotes rebound MET signaling. 
A) Heat map of phosphoproteins response to inhibitor withdrawal obtained by MesoScale 
analysis. The color scale bar represents relative protein phosphorylation changes calculated as 
log2 of the mean of two independent experiments done in duplicates. Phospho-ERK p< 0.03; 
phospho-AKT p< 0.007. B) Bar graphs showing the percentage of S-phase H1993 and EBC-
1 cells treated with JNJ-605 and released for the time indicated on bottom. Values are the 
mean of three independent experiments ± s.e.m. 
 
Figure 6. Rebound effects caused by inhibitor removal are prevented by MvDN30 
treatment. 
A) Immunoblotting of total cellular lysates from EBC-1 cells treated over night with 500nM 
JNJ-605, released from inhibition, and lysed at different time points (4h, 8h, 24h and 48h 
after washout). CTR, untreated cells; JNJ-605, cells that were not released; 24h+MvDN30, 
cells that were released from JNJ-605 and kept in presence of the MvDN30 antibody for 24 
hours; 24h+Fab unr., cells that were released in presence of an unrelated Fab antibody for 24 
hours. B) Bar graphs showing the percentage of S-phase EBC-1 cells treated as in (A). 
Values are the mean of three independent experiments ± s.e.m. C) EBC-1 and Hs746T cells 
were mock treated (CTR) or treated with MvDN30 [57.4 μg/ml] (MvDN30) overnight. Cells 
were released from the treatment through a washout procedure identical to the one used for 
JNJ-605 (24h MvDN30 washout) and lysed 24 hours later. Total cell lysates were blotted as 
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indicated on the left. Detection of AKT and ERK was done on different gels (with phospho 
and total proteins on the same gel). D) Bar graph showing the % of EBC-1 cells in S-phase in 
the samples indicated below (means ± SD, n = 4).  
 
Figure 7.  Rebound effects are prevented by MvDN30 in vivo. 
A) Experimental design. B) Bar graph showing the % of EdU-positive area normalized for 
DAPI staining (means ± s.e.m,; 8 fields/tumor were quantified). C) Representative merged 
confocal images of tumor sections showing the nuclei in blue and the EdU-positive cells in 
red. Bar is 50 μm. D) Representative images from tumor sections analyzed by 
immunohistochemistry with anti phospho-MET (top panel) and anti phospho-ERK (bottom 
panel) antibodies. In the phospho-MET panel, magnifications are also shown in the insets. 
Bar is 50 μm. E) Curves (means ± s.e.m.) refer to tumor volumes normalized on day 23 in 
mice treated as indicated in the legend.  
 
 
 
 
 
 
 
 
 
 
 
 







